Verdence Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.54M | Sell |
25,316
-2,205
| -8% | -$129K | 0.09% | 214 |
|
|
2025
Q4 | $1.48M | Sell |
27,521
-179
| -0.6% | -$8.61K | 0.09% | 209 |
|
|
2025
Q3 | $1.2M | Sell |
27,700
-2,539
| -8% | -$119K | 0.07% | 272 |
|
|
2025
Q2 | $1.4M | Sell |
30,239
-30,642
| -50% | -$1.5M | 0.1% | 207 |
|
|
2025
Q1 | $3.71M | Sell |
60,881
-5,871
| -9% | -$342K | 0.28% | 90 |
|
|
2024
Q4 | $3.78M | Sell |
66,752
-12,042
| -15% | -$673K | 0.3% | 83 |
|
|
2024
Q3 | $4.08M | Buy |
78,794
+4,958
| +7% | +$233K | 0.32% | 72 |
|
|
2024
Q2 | $3.07M | Buy |
73,836
+12,599
| +21% | +$564K | 0.27% | 93 |
|
|
2024
Q1 | $3.32M | Buy |
61,237
+18,564
| +44% | +$946K | 0.3% | 88 |
|
|
2023
Q4 | $2.19M | Buy |
42,673
+1,433
| +3% | +$75.2K | 0.21% | 121 |
|
|
2023
Q3 | $2.39M | Sell |
41,240
-6,979
| -14% | -$428K | 0.26% | 103 |
|
|
2023
Q2 | $3.08M | Buy |
48,219
+227
| +0.5% | +$15.2K | 0.36% | 71 |
|
|
2023
Q1 | $3.33M | Sell |
47,992
-478
| -1% | -$33.7K | 0.4% | 64 |
|
|
2022
Q4 | $3.49M | Sell |
48,470
-3,490
| -7% | -$263K | 0.43% | 52 |
|
|
2022
Q3 | $3.69M | Sell |
51,960
-5,959
| -10% | -$432K | 0.51% | 47 |
|
|
2022
Q2 | $4.46M | Sell |
57,919
-10,790
| -16% | -$822K | 0.58% | 40 |
|
|
2022
Q1 | $5.02M | Sell |
68,709
-45,133
| -40% | -$3.03M | 0.57% | 41 |
|
|
2021
Q4 | $7.1M | Buy |
113,842
+6,023
| +6% | +$353K | 0.84% | 24 |
|
|
2021
Q3 | $6.38M | Buy |
107,819
+13,947
| +15% | +$918K | 0.84% | 25 |
|
|
2021
Q2 | $6.27M | Buy |
93,872
+24,460
| +35% | +$1.59M | 0.87% | 22 |
|
|
2021
Q1 | $4.38M | Sell |
69,412
-348
| -0.5% | -$21.7K | 0.74% | 30 |
|
|
2020
Q4 | $4.33M | Buy |
69,760
+715
| +1% | +$44K | 0.82% | 22 |
|
|
2020
Q3 | $4.16M | Buy |
69,045
+52,445
| +316% | +$3.16M | 0.95% | 19 |
|
|
2020
Q2 | $976K | Buy |
16,600
+4,754
| +40% | +$284K | 0.24% | 108 |
|
|
2020
Q1 | $660K | Sell |
11,846
-84
| -0.7% | -$5.13K | 0.2% | 130 |
|
|
2019
Q4 | $766K | Buy |
11,930
+1,882
| +19% | +$108K | 0.19% | 127 |
|
|
2019
Q3 | $510K | Buy |
10,048
+1,174
| +13% | +$55.2K | 0.14% | 168 |
|
|
2019
Q2 | $402K | Buy |
8,874
+132
| +2% | +$6.15K | 0.12% | 193 |
|
|
2019
Q1 | $417K | Buy |
8,742
+115
| +1% | +$5.73K | 0.11% | 177 |
|
|
2018
Q4 | $448K | Buy |
8,627
+49
| +0.6% | +$2.63K | 0.13% | 152 |
|
|
2018
Q3 | $532K | Sell |
8,578
-1,169
| -12% | -$69.4K | 0.13% | 159 |
|
|
2018
Q2 | $539K | Sell |
9,747
-1,049
| -10% | -$56.7K | 0.13% | 162 |
|
|
2018
Q1 | $683K | Sell |
10,796
-1,407
| -12% | -$90.5K | 0.16% | 142 |
|
|
2017
Q4 | $748K | Buy |
+12,203
| New | +$763K | 0.18% | 107 |
|
Other funds holding BMY
VCM
VPM
Verdence Capital Advisors's BMY Position: Q1 2026 in Review
Verdence Capital Advisors reduced its Bristol-Myers Squibb (BMY) stake by 8% in Q1 2026, selling an estimated $129K and leaving 25,316 shares worth $1.54M. The position accounts for 0.09% of the portfolio, ranked #214.
Verdence Capital Advisors first reported a position in BMY in Q4 2017 and has held it in 34 quarters since. The position peaked at $7.1M in Q4 2021. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Verdence Capital Advisors held 25,316 shares of Bristol-Myers Squibb worth $1.54M as of Q1 2026.
- Verdence Capital Advisors sold 2,205 Bristol-Myers Squibb shares in Q1 2026, an estimated $129K.
- Bristol-Myers Squibb made up 0.09% of Verdence Capital Advisors's portfolio in Q1 2026, its #214 holding.
- Verdence Capital Advisors first reported a position in Bristol-Myers Squibb in Q4 2017 and has held it in 34 quarters since.
- Verdence Capital Advisors's Bristol-Myers Squibb position peaked at $7.1M in Q4 2021.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Verdence Capital Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.